Evidence map›Paper›PMID 39361899›Full record

ArticleBioscience reports2024

Extracellular bimolecular fluorescence complementation for investigating membrane protein dimerization: a proof of concept using class B GPCRs.

Michael L Garelja, Tyla I Alexander, Christopher S Walker, Debbie L Hay

Abstract read
In one paragraph

Article in Bioscience reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michael L GareljaDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, 9016, New Zealand.ORCID 0000-0001-5332-1236
Tyla I AlexanderDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, 9016, New Zealand.
Christopher S WalkerSchool of Biological Sciences, University of Auckland, Auckland, 1010, New Zealand.
Debbie L HayDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, 9016, New Zealand.

Funding

Target validation of a novel CGRP receptor in migraineRF1NS113839 · NINDS · UNIVERSITY OF IOWA · PI HAY, DEBBIE L, RUSSO, ANDREW F · 2019 to 2019
$3.1M
Health Research Council of New Zealand (HRC)National Institute of Neurological Disorders and Stroke (NINDS) RF1NS113839Neurological Foundation of New ZealandNINDS NIH HHS RF1 NS113839
6 · The paper itself

Abstract

Bimolecular fluorescence complementation (BiFC) methodology uses split fluorescent proteins to detect interactions between proteins in living cells. To date, BiFC has been used to investigate receptor dimerization by splitting the fluorescent protein between the intracellular portions of different receptor components. We reasoned that attaching these split proteins to the extracellular N-terminus instead may improve the flexibility of this methodology and reduce the likelihood of impaired intracellular signal transduction. As a proof-of-concept, we used receptors for calcitonin gene-related peptide, which comprise heterodimers of either the calcitonin or calcitonin receptor-like receptor in complex with an accessory protein (receptor activity-modifying protein 1). We created fusion constructs in which split mVenus fragments were attached to either the C-termini or N-termini of receptor subunits. The resulting constructs were transfected into Cos7 and HEK293S cells, where we measured cAMP production in response to ligand stimulation, cell surface expression of receptor complexes, and BiFC fluorescence. Additionally, we investigated ligand-dependent internalization in HEK293S cells. We found N-terminal fusions were better tolerated with regards to cAMP signaling and receptor internalization. N-terminal fusions also allowed reconstitution of functional fluorescent mVenus proteins; however, fluorescence yields were lower than with C-terminal fusion. Our results suggest that BiFC methodologies can be applied to the receptor N-terminus, thereby increasing the flexibility of this approach, and enabling further insights into receptor dimerization.

Indexed as

Protein MultimerizationAnimalsCalcitonin Receptor-Like ProteinChlorocebus aethiopsCOS CellsCyclic AMPHEK293 CellsHumansLuminescent ProteinsProof of Concept StudyReceptor Activity-Modifying Protein 1Receptors, CalcitoninRecombinant Fusion ProteinsSignal TransductionCalcitonin Receptor-Like ProteinCALCRL protein, humanCyclic AMPLuminescent ProteinsReceptor Activity-Modifying Protein 1Receptors, CalcitoninRecombinant Fusion ProteinsBimolecular Fluorescence ComplementationCalcitonin gene-related peptidecalcitonin receptordimerizationg protein-coupled receptorsreceptor activity-modifying protein

Identifiers

PMID39361899
PMCPMC11499381

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.